Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $187,742,000 across 4 holdings for the quarter ended 2019-03-31, in a 13F-HR filed 2019-05-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001606074-19-000002

Period
2019-03-31
Reported value
$188M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Stakes and trades reported after 2019-03-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CONSTELLATION PHARMACEUTICALadded+1$13

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q1 2019

Share positions as resolved from 13F-HR 0001606074-19-000002, largest first. % of portfolio is the value over $187,742,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 4,677,938 shares; 2019Q1: 4,677,939 shares 4,677,939$63.4M33.76%+1
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,540,850 shares; 2019Q1: 3,540,850 shares 3,540,850$44.2M23.56%0Timeline
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,102,934 shares; 2019Q1: 3,102,934 shares 3,102,934$41.3M21.98%0
IMMUNE DESIGN CORP.IMMUNE DESIGN CORP.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 6,642,942 shares; 2019Q1: 6,642,942 shares 6,642,942$38.9M20.7%0

How Q1 2019 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001606074-19-000002 base2019-05-08acceptance time not in the bulk data set